Medtronic Receives First-of-Its-Kind Approval for BrainSense™ Adaptive DBS and Electrode Identifier

Medtronic has received FDA approval for its BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), advancing personalised treatment for Parkinson’s disease.

DBS, a key therapy for neurological disorders, has been enhanced with BrainSense™ Adaptive technology, allowing real-time adjustments based on brain activity.

This innovation optimises symptom management, reducing the need for manual intervention.

This innovation integrates brain-computer interface (BCI) technology, playing a key role in developing advanced treatments aimed at managing Parkinson’s symptoms and enhancing rehabilitation. BrainSense™ Adaptive DBS is available for patients already implanted with a Percept™ neurostimulator, as well as those undergoing future DBS procedures.

Medtronic is the only company offering an adaptive DBS system that dynamically adjusts therapy. This sets a new standard in Parkinson’s care.

The ADAPT-PD trial, the most extensive study of aDBS, demonstrated its potential for improved symptom control. Additionally, the BrainSense™ EI reduces DBS programming time by 85%, enhancing efficiency for clinicians.

The BrainSense™ Electrode Identifier simplifies and improves electrode selection by providing real-time insights into a patient’s brain signals.